Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLM + Axitinib + Pembrolizumab in Advanced ccRCC
NCT05363631Phase 2Completed
- Start
- Sep 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selenomethionine in clear cell renal cell carcinoma (ccRCC). Primary endpoints: Dose Limiting Toxicities at 3 years and Objective Response Rate at 3 years. Started Sep 2022; status: completed.
02
Drugs
selenomethionine
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05363631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05363631.